ValiRx’s published study of VAL401, a single dose in an open-label trial of late-stage cancer patients, provide support for future studies of VAL401 as a cancer treatment, as the Cmaxdemonstrates sufficient exposure to reach the concentrations seen during preclinical anticancer testing, yet the overall exposure to the active moiety supports the use of the safety and tolerability data from conventional risperidone during future clinical trials.
The study was published in European Journal of Drug Metabolism and Pharmacokinetics. VAL401 was tested in the treatment of patients with locally advanced or metastatic non-small cell lung adenocarcinoma.
In a conclusion, the researches said that although this study was developed with the intention to repurpose risperidone for use as a treatment for adenocarcinoma, these pharmacokinetic data on a previously unexplored formulation may also be considered in the context of the treatment of psychosis.